{"prompt": "['Novartis', 'Confidential', 'Page 43', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Period', 'Screening', 'Run-in', 'Treatment', 'Follow-up', 'Study', 'Completion', 'Visit number', '1', '101', '201', '202', '203', '204', 'TD', '3014', 'Day', '-21 to -14', '-14', '1', '57', '113', '169', '176', 'Week', '-3 to -2*', '-2', '0', '8', '16', '24', '25', 'Reversibility Spirometry test(SABA\u00b3', 'X', 'Spirometry', 'X', 'Safety', 'Lab', 'assessments', 'X', '(haematology, clinical chemistry,', 'urinalysis, blood eosinophil count)', 'Issue and train on eDiary /', 'S', 'S', 'S', 'S', 'S', 'S', 'Review eDiary /', 'S', 'S', 'S', 'S', 'S', 'AccuhalerR device training', 'S', 'Dispense Run-in medication via IRT', 'S', 'Issue Run-in medication', 'X', 'Randomization via IRT', 'S', 'Dispense study treatment via IRT', 'S', 'S', 'S', 'Concept1', 'or', 'Accuhaler', '+', 'S', 'S', 'S', 'Respimat device training', 'Study Treatment Compliance', 'X', 'Study treatment administration at', 'visit', 'AEs recording', 'X\u00b2', 'X', 'X', 'SAEs recording', 'X', 'X', 'ACQ-7', 'X', 'AQLQ', 'Survival Status', 'X', '* Time between Visit 1 and 101 can be shortened/adapted according to the required wash-out from previous', 'asthma medication.', 'TD: Trial discontinuation', 'S: These assessments are source documentation only and will not be entered into the e-CRF', 'X: Assessment to be reported in the clinical database']['Novartis', 'Confidential', 'Page 44', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '1 For females of child-bearing potential only unless surgically sterile.', '2 If patient is screen failure, any non-serious AEs must only be recorded in the source documentation (S)', '3 If reversibility fails on the first attempt at V101, historical reversibility or bronchoprovocation would be acceptable', 'as specified in Section 4.1', \"4 Information about patients' status will be obtained by a telephone call, 7 days after the patient's last dose of\", 'study drug for completed patients or at any time during the study treatment period when indicated. For patients', 'who withdraw early, please refer to discontinuation of study treatment and premature patient withdrawal section.', 'Table 6-2 Timed Assessments', 'Visit', 'Timepoint\u00b9', 'PROs', 'Spirometry4', 'Labs', 'Urine', 'ECG', '(Day)', '(AQLQ, ACQ-7,', '(FEV1, FVC)', '(Hematology,', 'Pregnancy', 'Vitals\u00b2', 'Chemistry,', 'Test\u00b3', 'Urinalysis)', 'Visit 201', '>-45 min', 'X', 'X', '(Day 1)', '-45 min', 'X', '- -15 min', 'X', '0 min', 'EVENING DOSE', 'Visit 202', '>-45 min', 'X', '(Day 57)', '-45 min', 'X', '-15 min', 'X', '0 min', 'EVENING DOSE', 'Visit 203', '>-45 min', 'X', 'X', '(Day 113)', '-45 min', 'X', '-15 min', 'X', '0 min', 'EVENING DOSE', 'Visit 204', '>-45 min', 'X', '(Day 169)', '- 45 min', 'X', '- 45 to -20', 'X5,6', 'min', '- -15 min', 'X', '0 min', 'EVENING DOSE', '1', 'Study drug timed doses. All study medication doses to be administered in the clinic. Time relates to the dose', 'given from first device at visit. >-45 refers to any time before the -45 spirometry time point. Assessments', 'scheduled -45 to -20 min can be done at any time pre-dose if more convenient or efficient.', '2 Systolic and diastolic blood pressure and heart rate (radial pulse)', '3', 'Urine pregnancy test can be done at any time pre-dose if more convenient or efficient.', '4', 'A minimum of 3 minutes rest must be observed prior to the start of spirometry at each time-point. A minimum of', '1 minute rest is to be observed between each spirometry maneuver.', '5 Urine analysis is to be done only if the urine dipstick is abnormal, and only done pre-dose', '6 Serum pregnancy test done with safety labs at Visit 204', '6.1 Information to be collected on screening failures', 'All patients who have signed informed consent but not entered into the run-in period will have', 'the screening disposition page for the screening period, demographics, eligibility criteria, and', 'serious adverse events (SAE) data collected. Adverse events that are not SAEs will be', 'followed by the investigator and collected only in the source data only.']\n\n###\n\n", "completion": "END"}